Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

hVIVO: Broker rates the rates the contract research group one of its best investment ideas for 2023

Broker Liberum has identified hVIVO PLC as one of its best investment ideas for 2023.

This is based on the company's strong performance in 2022, as highlighted in Wednesday's trading statement.

The update showed sustainable revenue growth, as well as an outperformance in both the EBITDA margin and cash generation, Liberum said.

The healthy contracted order book also gives 95% visibility over 2023 revenue expectations, with the potential for upgrades later in the year, it added.

Liberum said the high underlying margin profile also drives a structural 4-5% upgrade to EBITDA throughout the forecast period.

As a result, the broker has increased its target price for hVIVO shares from 21.60p to 25.10p and maintained its 'strong buy' rating.

In afternoon trade, the stock was changing hands for 17.47p, up 17.3% on the day.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK